2024
DOI: 10.1297/cpe.2024-0004
|View full text |Cite
|
Sign up to set email alerts
|

Clinical management of diazoxide-unresponsive congenital hyperinsulinism: A single-center experience

Kei Takasawa,
Ryosei Iemura,
Ryuta Orimoto
et al.

Abstract: Highlights •Despite clinical advances in the management of CHI, treatment options remain limited.• A maximum dose of octreotide (25 μg/kg/d) can safely replace lanreotide 60 mg.• Home-based CGM is useful for determining therapeutic strategy and management.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 42 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?